The Common Cold: Potential for Future Prevention or Cure

  • Maria Passioti
  • Paraskevi MagginaEmail author
  • Spyridon Megremis
  • Nikolaos G. Papadopoulos
Part of the following topical collections:
  1. Topical Collection on Rhinosinusitis


The common cold is the most frequent, although generally mild, human disease. Human Rhinoviruses are the prevalent causative agents, but other viruses are also implicated. Being so common, viral colds, have significant implications on public health and quality of life, but may also be life-threatening for vulnerable groups of patients. Specific diagnosis and treatment of the common cold still remain unmet needs. Molecular diagnostic techniques allow specific detection of known pathogens as well as the identification of newly emerging viruses. Although a number of medications or natural treatments have been shown to have some effect, either on the number or on the severity of common colds, no single agent is considerably effective. Virus-specific management remains in most cases a challenging potential as many factors have to be taken into account, including the diversity of the viral genomes, the heterogeneity of affected individuals, as well as the complexity of this long standing host-virus relationship.


Common cold Prevention Cure Rhinovirus Upper respiratory tract infections Antiviral therapy Vaccines Influenza RSV Molecular diagnosis Management Passive immunization Vaccination 


Compliance with Ethics Guidelines

Conflict of Interest

Nikolaos G. Papadopoulos has served as a consultant for AbbVie, Novartis, Menarini, and Meda; has received grant support from Merck, Sharp & Dohme, Nestle, and GlaxoSmithKline; has received payment for giving lectures/serving on speakers bureaus from Novartis, Uriach, GlaxoSmithKline, Allergopharma, and Stallergen; and has received payment for development of educational presentations from Uriach and Meda.

Maria Passioti, Paraskevi Maggina, and Spyridon Megremis declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of important •• Of major important

  1. 1.
    Fokkens WJ et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;23:3. p preceding table of contents, 1–298.PubMedGoogle Scholar
  2. 2.
    Heikkinen T, Jarvinen A. The common cold. Lancet. 2003;361(9351):51–9.PubMedGoogle Scholar
  3. 3.
    Roelen CA, Koopmans PC, Notenbomer A, Groothoff JW, et al. Job satisfaction and short sickness absence due to the common cold. Work. 2011;39(3):305–13.PubMedGoogle Scholar
  4. 4.
    Kenealy T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev. 2013;6, CD000247.PubMedGoogle Scholar
  5. 5.
    Leder K, Sinclair MI, Mitakakis TZ, Hellard ME, Forbes A. A community-based study of respiratory episodes in Melbourne, Australia. Aust N Z J Public Health. 2003;27(4):399–404.PubMedGoogle Scholar
  6. 6.
    Gruber C et al. History of respiratory infections in the first 12 yr among children from a birth cohort. Pediatr Allergy Immunol. 2008;19(6):505–12.PubMedGoogle Scholar
  7. 7.
    Ball TM et al. Influence of attendance at day care on the common cold from birth through 13 years of age. Arch Pediatr Adolesc Med. 2002;156(2):121–6.PubMedGoogle Scholar
  8. 8.
    Pitkaranta A et al. Lowered yields of virus-induced interferon production in leukocyte cultures and risk of recurrent respiratory infections in children. J Clin Virol. 1999;14(3):199–205.PubMedGoogle Scholar
  9. 9.
    Cohen S et al. Positive emotional style predicts resistance to illness after experimental exposure to rhinovirus or influenza a virus. Psychosom Med. 2006;68(6):809–15.PubMedGoogle Scholar
  10. 10.
    Herlov-Nielsen H, Permin H. Common cold–risk factors, transmission and treatment. Ugeskr Laeger. 2001;163(41):5643–6.PubMedGoogle Scholar
  11. 11.
    Nieman DC. Exercise, upper respiratory tract infection, and the immune system. Med Sci Sports Exerc. 1994;26(2):128–39.PubMedGoogle Scholar
  12. 12.
    Makela MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36(2):539–42.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Monto AS. Epidemiology of viral respiratory infections. Am J Med. 2002;112(Suppl 6A):4S–12S.PubMedGoogle Scholar
  14. 14.
    Grief SN. Upper respiratory infections. Prim Care. 2013;40(3):757–70.PubMedGoogle Scholar
  15. 15.
    Jartti T, Jartti L, Ruuskanen O, Söderlund-Venermo M. New respiratory viral infections. Curr Opin Pulm Med. 2012;18(3):271–8.PubMedGoogle Scholar
  16. 16.
    Weigl JA et al. Ten years' experience with year-round active surveillance of up to 19 respiratory pathogens in children. Eur J Pediatr. 2007;166(9):957–66.PubMedGoogle Scholar
  17. 17.
    Kahn J. Human bocavirus: clinical significance and implications. Curr Opin Pediatr. 2008;20(1):62–6.PubMedGoogle Scholar
  18. 18.
    Gwaltney Jr JM et al. Rhinovirus infections in an industrial population. I. The occurrence of illness. N Engl J Med. 1966;275(23):1261–8.PubMedGoogle Scholar
  19. 19.
    Monto AS, Johnson KM. A community study of respiratory infections in the tropics. II. The spread of six rhinovirus isolates within the community. Am J Epidemiol. 1968;88(1):55–68.PubMedGoogle Scholar
  20. 20.
    Briese T et al. Global distribution of novel rhinovirus genotype. Emerg Infect Dis. 2008;14(6):944–7.PubMedGoogle Scholar
  21. 21.
    Arakawa M, Okamoto-Nakagawa R, Toda S, Tsukagoshi H, Kobayashi M, Ryo A. Molecular epidemiological study of human rhinovirus species A, B and C from patients with acute respiratory illnesses in Japan. J Med Microbiol. 2012;61(3):410–9.PubMedGoogle Scholar
  22. 22.
    Jefferson T, Del Mar C, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2011;7, CD006207.PubMedGoogle Scholar
  23. 23.
    Gern JE et al. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med. 2000;162(6):2226–31.PubMedGoogle Scholar
  24. 24.•
    Jacobs SE et al. Human rhinoviruses. Clin Microbiol Rev. 2013;26(1):135–62. This review provides a summary of pathogenesis, clinical epidemiology, and laboratory features of and treatment and prevention strategies for RVs. PubMedCentralPubMedGoogle Scholar
  25. 25.
    Winther B et al. Light and scanning electron microscopy of nasal biopsy material from patients with naturally acquired common colds. Acta Otolaryngol. 1984;97(3–4):309–18.PubMedGoogle Scholar
  26. 26.•
    Triantafilou K, Vakakis E, Richer EA, Evans GL, Villiers JP, Triantafilou M. Human rhinovirus recognition in non-immune cells is mediated by Toll-like receptors and MDA-5, which trigger a synergetic pro-inflammatory immune response. Virulence. 2011;2(1):22–9. This article gives insight on the host's immune response mechanisms during common cold caused by rhinovirus that give rise to inflammation that defines common cold symptoms. PubMedGoogle Scholar
  27. 27.
    Papadopoulos NG et al. Rhinoviruses infect the lower airways. J Infect Dis. 2000;181(6):1875–84.PubMedGoogle Scholar
  28. 28.
    Lessler J et al. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291–300.PubMedGoogle Scholar
  29. 29.
    Harris 2nd JM, Gwaltney Jr JM. Incubation periods of experimental rhinovirus infection and illness. Clin Infect Dis. 1996;23(6):1287–90.PubMedGoogle Scholar
  30. 30.
    Gwaltney Jr JM, Hendley JO, Patrie JT. Symptom severity patterns in experimental common colds and their usefulness in timing onset of illness in natural colds. Clin Infect Dis. 2003;36(6):714–23.PubMedGoogle Scholar
  31. 31.
    Iwane MK, Prill MM, Lu X, Miller EK, Edwards KM, Hall CB. Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children. J Infect Dis. 2011;204(11):1702–10.PubMedGoogle Scholar
  32. 32.
    Singleton RJ, Bulkow LR, Miernyk K, DeByle C, Pruitt L, Hummel KB. Viral respiratory infections in hospitalized and community control children in Alaska. J Med Virol. 2010;82(7):1282–90.PubMedGoogle Scholar
  33. 33.
    Graat JM, Schouten EG, Heijnen ML, Kok FJ, Pallast EG, de Greeff SC, et al. A prospective, community-based study on virologic assessment among elderly people with and without symptoms of acute respiratory infection. J Clin Epidemiol. 2003;56(12):1218–23.PubMedGoogle Scholar
  34. 34.
    Armengol CE, Hendley JO, Winther B. Occurrence of acute otitis media during colds in children younger than four years. Pediatr Infect Dis J. 2011;30(6):518–20.PubMedGoogle Scholar
  35. 35.
    Marom T, Nokso-Koivisto J, Chonmaitree T. Viral-bacterial interactions in acute otitis media. Curr Allergy Asthma Rep. 2000;12(6):551–8.Google Scholar
  36. 36.
    Esposito S, Marchisio P, Tenconi R, Tagliaferri L, Albertario G, Patria MF, et al. Diagnosis of acute rhinosinusitis. Pediatr Allergy Immunol. 2012;23(22):17–9.PubMedGoogle Scholar
  37. 37.
    Welge-Lussen A, Wolfensberger M. Olfactory disorders following upper respiratory tract infections. Adv Otorhinolaryngol. 2006;63:125–32.PubMedGoogle Scholar
  38. 38.
    Papadopoulos NG. Do rhinoviruses cause pneumonia in children? Paediatr Respir Rev. 2004;5(A):S191–5.PubMedGoogle Scholar
  39. 39.
    Ruuskanen O et al. Viral pneumonia. Lancet. 2011;377(9773):1264–75.PubMedGoogle Scholar
  40. 40.
    Corne JM et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359(9309):831–4.PubMedGoogle Scholar
  41. 41.
    Papadopoulos NG et al. Viruses and bacteria in acute asthma exacerbations–a GA(2) LEN-DARE systematic review. Allergy. 2011;66(4):458–68.PubMedGoogle Scholar
  42. 42.
    Wark PA et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–47.PubMedCentralPubMedGoogle Scholar
  43. 43.
    Kherad O, Kaiser L, Bridevaux PO, Sarasin F, Thomas Y, Janssens JP, et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest. 2010;138(4):896–904.PubMedGoogle Scholar
  44. 44.
    de Almeida MB, Zerbinati RM, Tateno AF, Oliveira CM, Romão RM, Rodrigues JC, et al. Rhinovirus C and respiratory exacerbations in children with cystic fibrosis. Emerg Infect Dis. 2010;16(6):996–9.PubMedGoogle Scholar
  45. 45.
    Crooks BN, Taylor CE, Turner AJ, Osman HK, Abinun M, Flood TJ, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant. 2000;26(10):1097–102.PubMedGoogle Scholar
  46. 46.•
    Kraft CS, Jacob JT, Sears MH, Burd EM, Caliendo AM, Marshall Lyon G. Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza. J Clin Microbiol. 2012;50(3):1061–3. This study demonstrates that human rhinovirus infection is associated with significant morbidity and mortality in immunocompromised individuals. PubMedCentralPubMedGoogle Scholar
  47. 47.
    Luinstra K, Petrich A, Castriciano S, Ackerman M, Chong S, Carruthers S, et al. Evaluation and clinical validation of an alcohol-based transport medium for preservation and inactivation of respiratory viruses. J Clin Microbiol. 2011;49(6):2138–42.PubMedCentralPubMedGoogle Scholar
  48. 48.
    Landry ML, Cohen S, Ferguson D. Impact of sample type on rapid detection of influenza virus A by cytospin-enhanced immunofluorescence and membrane enzyme-linked immunosorbent assay. J Clin Microbiol. 2000;38(1):429–30.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Jartti T, Hedman K, Jartti L, Ruuskanen O, Allander T, Söderlund-Venermo M. Human bocavirus-the first 5 years. Rev Med Virol. 2012;22(1):46–64.PubMedGoogle Scholar
  50. 50.
    Mahony JB, Petrich A, Smieja M. Molecular diagnosis of respiratory virus infections. Crit Rev Clin Lab Sci. 2011;48(5–6):217–49.PubMedGoogle Scholar
  51. 51.
    Jartti T, Söderlund-Venermo M, Hedman K, Ruuskanen O, Mäkelä MJ. New molecular virus detection methods and their clinical value in lower respiratory tract infections in children. Paediatr Respir Rev. 2013;14(1):38–45.PubMedGoogle Scholar
  52. 52.
    Turner RB, Fuls JL, Rodgers ND, Goldfarb HB, Lockhart LK, Aust LB. A randomized trial of the efficacy of hand disinfection for prevention of rhinovirus infection. Clin Infect Dis. 2012;54(10):1422–6.PubMedGoogle Scholar
  53. 53.•
    Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011;52(1):1–7. A clinical study of a novel influenza vaccine designed to boost cross-reactive immune responses to all influenza A subtypes. PubMedGoogle Scholar
  54. 54.
    Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, et al. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine. 2013;31(48):5706–12.PubMedGoogle Scholar
  55. 55.
    Simancas-Racines D, Guerra CV, Hidalgo R. Vaccines for the common cold. Cochrane Database Syst Rev. 2013;6, CD002190.PubMedGoogle Scholar
  56. 56.
    Fu YH, He JS, Qiao W, Jiao YY, Hua Y, Zhang Y, et al. Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice. Virol J. 2013;10:183.PubMedCentralPubMedGoogle Scholar
  57. 57.•
    Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One. 2012;7(5):e36812. Study describing a safe and effective intramuscular virosomal RSV vaccine adjuvanted with Monophosphoryl Lipid A in mice. PubMedCentralPubMedGoogle Scholar
  58. 58.•
    Rigter A, Widjaja I, Versantvoort H, Coenjaerts FEJ, van Roosmalen M, Leenhouts K, et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS One. 2013;8(8):e71072. Study describing a safe and effective intranasal vaccine in mice and cotton rats that is based on recombinant fusion (F) protein bound to the surface of immunostimulatory bacterium. PubMedCentralPubMedGoogle Scholar
  59. 59.
    Palmenberg AC et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science. 2009;324(5923):55–9.PubMedGoogle Scholar
  60. 60.•
    Bochkov YA, Palmenberg AC, Lee WM, Rathe JA, Amineva SP, Sun X, et al. Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nat Med. 2011;17(5):627–32. Study describing for the first time the propagation of two HRV-C isolates in organ culture of nasal epithelial cells, sequencing a new C15 isolate, developed the first reverse genetics system for HRV-C and predicted a unique cell attachment site for HRV-Cs. PubMedCentralPubMedGoogle Scholar
  61. 61.•
    Megremis S, Demetriou P, Makrinioti H, Manoussaki AE, Papadopoulos NG. The genomic signature of human rhinoviruses A, B and C. PLoS One. 2012;7(9):e44557. Study presents for the first time the genomic signature of 111 fully sequenced HRV strains from all three groups HRV-A, HRV-B and HRV-C and propose a mechanism for the rapid changes in the HRV genomic sequence under the immune-driven pressures. PubMedCentralPubMedGoogle Scholar
  62. 62.
    Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med. 2008;14(2):199–204.PubMedCentralPubMedGoogle Scholar
  63. 63.••
    Niespodziana K, Napora K, Cabauatan C, Focke-Tejkl M, Keller W, Niederberger V, et al. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections. FASEB J. 2012;26(3):1001–8. Study describes how RV escapes immunity by misdirecting the human antibody response and causes recurrent infections. PubMedGoogle Scholar
  64. 64.
    Katpally U, Fu T-M, Freed DC, Casimiro DR, Smith TJ, et al. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J Virol. 2009;83(14):7040–8.PubMedCentralPubMedGoogle Scholar
  65. 65.•
    McLean GR, Walton RP, Shetty S, Peel TJ, Paktiawal N, Kebadze T, et al. Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1. Antiviral Res. 2012;95(3):193–201. Study using mouse models to investigate antibody response to RV and reveals strong cross serotype RV-specific IgG responses against the RV capsid protein VP1. PubMedGoogle Scholar
  66. 66.
    Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4:CD006602.PubMedGoogle Scholar
  67. 67.
    Groothuis JR, Hoopes JM, Jessie VG. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther. 2011;28(2):91–109.PubMedGoogle Scholar
  68. 68.
    Schepens B, Ibañez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P. Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis. 2011;204(11):1692–701.PubMedGoogle Scholar
  69. 69.••
    Clementi N, De Marco D, Mancini N, Solforosi L, Moreno GJ, Gubareva LV, et al. A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS One. 2011;6(12):e28001. Study describing a human monoclonal antibody capable of neutralizing subtypes responsible of all the reported pandemics, as well as other subtypes with pandemic potential. PubMedCentralPubMedGoogle Scholar
  70. 70.••
    Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850–6. Study describing a neutralizing monoclonal antibody against both group 1 and group 2 influenza A viruses with broad specificity and neutralization potency. PubMedGoogle Scholar
  71. 71.
    Kim SY, Chang YJ, Cho HM, Hwang YW, Moon YS. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2013;6, CD006362.PubMedGoogle Scholar
  72. 72.
    Li S et al. Acetaminophen (paracetamol) for the common cold in adults. Cochrane Database Syst Rev. 2013;7, CD008800.PubMedGoogle Scholar
  73. 73.
    Simons FE. H1-antihistamines in children. Clin Allergy Immunol. 2002;17:437–64.PubMedGoogle Scholar
  74. 74.
    De Sutter AI, van Driel ML, Kumar AA, Lesslar O, Skrt A. Oral antihistamine-decongestant-analgesic combinations for the common cold. Cochrane Database Syst Rev. 2012;2:CD004976.PubMedGoogle Scholar
  75. 75.
    Meltzer EO, Caballero F, Scadding G. Treatment of congestion in upper respiratory diseases. Int J Gen Med. 2010;3:69–91.PubMedCentralPubMedGoogle Scholar
  76. 76.
    Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Muñoz E, et al. Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012;34(1):98–106.PubMedGoogle Scholar
  77. 77.
    Albalawi ZH, Othman SS, Alfaleh K. Intranasal ipratropium bromide for the common cold. Cochrane Database Syst Rev. 2013;6, CD008231.PubMedGoogle Scholar
  78. 78.
    Singh M. Heated, humidified air for the common cold. Cochrane Database Syst Rev. 2013;6, CD001728.PubMedGoogle Scholar
  79. 79.
    Baartmans M et al. Steam inhalation therapy: severe scalds as an adverse side effect. Br J Gen Pract. 2012;62(600):e473–7.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Dicpinigaitis PV. Cough: an unmet clinical need. Br J Pharmacol. 2011;163(1):116–24.PubMedGoogle Scholar
  81. 81.
    Sen EF, Verhamme KM, Felisi M, 't Jong GW, Giaquinto C, Picelli G, et al. Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age. Br J Clin Pharmacol. 2011;71(6):943–50.PubMedGoogle Scholar
  82. 82.
    Hayward G, Thompson MJ, Perera R, Del Mar CB, Glasziou PP, Heneghan CJ. Corticosteroids for the common cold. Cochrane Database Syst Rev. 2012;8:CD008116.PubMedGoogle Scholar
  83. 83.
    Barrett B et al. Echinacea for treating the common cold: a randomized trial. Ann Intern Med. 2010;153(12):769–77.PubMedCentralPubMedGoogle Scholar
  84. 84.
    Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev. 2013;6:CD001364.PubMedGoogle Scholar
  85. 85.
    Mao S, Huang S. Vitamin D supplementation and risk of respiratory tract infections: a meta-analysis of randomized controlled trials. Scand J Infect Dis. 2013;45(9):696–702.PubMedGoogle Scholar
  86. 86.
    Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid Biochem Mol Biol. 2013;136:321–9.PubMedGoogle Scholar
  87. 87.
    Bergman P, Lindh AU, Björkhem-Bergman L, Lindh JD, et al. Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013;8(6):e65835.PubMedCentralPubMedGoogle Scholar
  88. 88.•
    Science M, Maguire JL, Russell ML, Smieja M, Walter SD, Loeb M. Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents. Clin Infect Dis. 2013;57(3):392–7. This study demonstrate that low serum 25(OH) D levels are associated with increased risk of laboratory-confirmed viral RTI in children in a dose depending way. PubMedGoogle Scholar
  89. 89.
    Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA. 2012;308(13):1333–9.PubMedGoogle Scholar
  90. 90.
    Arroll B. Common cold. Am Fam Physician. 2011;84(12):1390–1.PubMedGoogle Scholar
  91. 91.
    Maggini S, Beveridge S, Suter M. A combination of high-dose vitamin C plus zinc for the common cold. J Int Med Res. 2012;40(1):28–42.PubMedGoogle Scholar
  92. 92.
    Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013;1, CD000980.PubMedGoogle Scholar
  93. 93.
    Linde K, Barrett B, Wölkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006;1, CD000530.PubMedGoogle Scholar
  94. 94.
    Nahas R, Balla A. Complementary and alternative medicine for prevention and treatment of the common cold. Can Fam Physician. 2011;57(1):31–6.PubMedCentralPubMedGoogle Scholar
  95. 95.
    Jawad M et al. Safety and efficacy profile of echinacea purpurea to prevent common cold episodes: a randomized, double-blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med. 2012;2012:841315.PubMedCentralPubMedGoogle Scholar
  96. 96.
    Kang EJ, Kim SY, Hwang IH, Ji YJ. The effect of probiotics on prevention of common cold: a meta-analysis of randomized controlled trial studies. Korean J Fam Med. 2013;34(1):2–10.PubMedCentralPubMedGoogle Scholar
  97. 97.
    Hao Q, Lu Z, Dong BR, Huang CQ, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2011;9, CD006895.PubMedGoogle Scholar
  98. 98.
    Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54(5):682–7.PubMedGoogle Scholar
  99. 99.
    Shinkai S, Toba M, Saito T, Sato I, Tsubouchi M, Taira K, et al. Immunoprotective effects of oral intake of heat-killed Lactobacillus pentosus strain b240 in elderly adults: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2013;109(10):1856–65.PubMedGoogle Scholar
  100. 100.
    Marotta F et al. Is there a potential application of a fermented nutraceutical in acute respiratory illnesses? An in-vivo placebo-controlled, cross-over clinical study in different age groups of healthy subjects. J Biol Regul Homeost Agents. 2012;26(2):285–94.PubMedGoogle Scholar
  101. 101.•
    Ganesan S, Faris AN, Wang Q, Nanua S, Hershenson MB, et al. Quercetin inhibits rhinovirus replication in vitro and in vivo. Antiviral Res. 2012;94(3):258–71. Study demonstrating in vivo and in vitro that quercetin decreases RV infection at multiple steps in the viral life cycle. PubMedCentralPubMedGoogle Scholar
  102. 102.
    Song JH, Park KS, Kwon DH, Choi HJ. Anti-human rhinovirus 2 activity and mode of action of quercetin-7-glucoside from Lagerstroemia speciosa. J Med Food. 2013;16(4):274–9.PubMedGoogle Scholar
  103. 103.
    Heinz SA, Henson DA, Austin MD, Jin F, Nieman DC. Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial. Pharmacol Res. 2010;62(3):237–42.PubMedGoogle Scholar
  104. 104.•
    Riede L, Grube B, Gruenwald J. Larch arabinogalactan effects on reducing incidence of upper respiratory infections. Curr Med Res Opin. 2013;29(3):251–8. A clinical trial demonstrating that larch arabinogalactan increase the body’s potential to defend against common cold infection. PubMedGoogle Scholar
  105. 105.
    Leibbrandt A, Meier C, König-Schuster M, Weinmüllner R, Kalthoff D, Pflugfelder B, et al. Iota-carrageenan is a potent inhibitor of influenza A virus infection. PLoS One. 2010;5(12):e14320.PubMedCentralPubMedGoogle Scholar
  106. 106.
    Grassauer A, Meier C, Pretsch A, Prieschl-Grassauer E, Unger H. Iota-carrageenan is a potent inhibitor of rhinovirus infection. Virol J. 2008;5:107.PubMedCentralPubMedGoogle Scholar
  107. 107.
    Eccles R, Meier C, Prieschl-Grassauer E. Efficacy and safety of an antiviral iota-carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res. 2010;11:108.PubMedCentralPubMedGoogle Scholar
  108. 108.
    Fazekas T, Eickhoff P, Pruckner N, Vollnhofer G, Fischmeister G, Diakos C, et al. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. BMC Complement Altern Med. 2012;12:147.PubMedCentralPubMedGoogle Scholar
  109. 109.
    Auinger A, Riede L, Bothe G, Busch R, Gruenwald J. Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body's defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects. Eur J Nutr. 2013;52(8):1913–8.PubMedCentralPubMedGoogle Scholar
  110. 110.
    Graubaum H-J, Busch R, Stier H, Gruenwald J. A doubleblind, randomized, placebo-controlled nutritional study using an insoluble yeast beta-glucan to improve the immune defense system. Food Nut Sci. 2012;3:738–46.Google Scholar
  111. 111.
    Yates PJ et al. Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza. Antimicrob Agents Chemother. 2013;57(4):1677–84.PubMedCentralPubMedGoogle Scholar
  112. 112.
    Michiels B et al. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013;8(4):e60348.PubMedCentralPubMedGoogle Scholar
  113. 113.
    Wang K et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev. 2012;4:CD002744.PubMedGoogle Scholar
  114. 114.
    Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev. 2010;23(1):74–98.PubMedCentralPubMedGoogle Scholar
  115. 115.•
    Olszewska W, Ispas G, Schnoeller C, Sawant D, Van de Casteele T, Nauwelaers D, et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J. 2011;38(2):401–8. This study describes a new antiviral agent that reduces RSV replication and inhibits lung inflammation in mice. PubMedGoogle Scholar
  116. 116.
    Sun Z et al. Respiratory syncytial virus entry inhibitors targeting the F protein. Virus. 2013;5(1):211–25.Google Scholar
  117. 117.
    Maugeri C et al. New anti-viral drugs for the treatment of the common cold. Bioorg Med Chem. 2008;16(6):3091–107.PubMedGoogle Scholar
  118. 118.
    Patick AK. Rhinovirus chemotherapy. Antiviral Res. 2006;71(2–3):391–6.PubMedGoogle Scholar
  119. 119.•
    Rollinger JM, Schmidtke M. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev. 2011;31(1):42–92. This is an extensive review of existing knowledge about mechanisms of anti-RV agents from synthetic and natural origin, and future potentials. PubMedGoogle Scholar
  120. 120.
    Gwaltney Jr JM et al. Combined antiviral-antimediator treatment for the common cold. J Infect Dis. 2002;186(2):147–54.PubMedGoogle Scholar
  121. 121.
    Gao L et al. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine. 2010;28(28):4445–51.PubMedGoogle Scholar
  122. 122.••
    Campbell-Harding G, Sawkins H, Bedke N, Holgate ST, Davies DE, Andrews AL, et al. The innate antiviral response upregulates IL-13 receptor alpha2 in bronchial fibroblasts. J Allergy Clin Immunol. 2013;131(3):849–55. This study enlightens the role of IFN-beta and IL-13 in innate antiviral immune response. PubMedGoogle Scholar
  123. 123.
    Yamaya M et al. Levofloxacin inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Antimicrob Agents Chemother. 2012;56(8):4052–61.PubMedCentralPubMedGoogle Scholar
  124. 124.
    Koutsoubari I et al. Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study. Pediatr Allergy Immunol. 2012;23(4):385–90.PubMedGoogle Scholar
  125. 125.
    Min JY, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators Inflamm. 2012;2012:649570.PubMedCentralPubMedGoogle Scholar
  126. 126.
    Jurgeit A et al. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog. 2012;8(10):e1002976.PubMedCentralPubMedGoogle Scholar
  127. 127.
    Yoshihara S et al. Inhibition of common cold-induced aggravation of childhood asthma by leukotriene receptor antagonists. Allergol Int. 2012;61(3):405–10.PubMedGoogle Scholar
  128. 128.
    Kozer E et al. RCT of montelukast as prophylaxis for upper respiratory tract infections in children. Pediatrics. 2012;129(2):e285–90.PubMedGoogle Scholar
  129. 129.
    Kloepfer KM. Effects of montelukast on patients with asthma after experimental inoculation with human rhinovirus 16. Ann Allergy Asthma Immunol. 2011;106(3):252–7.PubMedCentralPubMedGoogle Scholar
  130. 130.
    Yamaya M et al. Inhibitory effects of tiotropium on rhinovirus infection in human airway epithelial cells. Eur Respir J. 2012;40(1):122–32.PubMedGoogle Scholar
  131. 131.
    Gern JE et al. Inhibition of rhinovirus replication in vitro and in vivo by acid-buffered saline. J Infect Dis. 2007;195(8):1137–43.PubMedGoogle Scholar
  132. 132.
    Van Blerkom LM. Role of viruses in human evolution. Am J Phys Anthropol. 2003;37:14–46.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Maria Passioti
    • 1
  • Paraskevi Maggina
    • 1
    Email author
  • Spyridon Megremis
    • 1
  • Nikolaos G. Papadopoulos
    • 1
  1. 1.Allergy & Clinical Immunology Research Center, 2nd Department of Paediatrics, ‘P&A Kyriakou’ Childrens’ HospitalUniversity of AthensAthensGreece

Personalised recommendations